Fig. 3

Co-depletion of PARG does not potentiate cytotoxicity by BRCA1 depletion. a Clonogenic survival (left panel) of MDA-MB-231 cells after single or combined siRNA-mediated depletion of BRCA1 and PARG. Results are depicted as box plots showing distribution of data from 4 individual experiments. Middle panel Percentage of viable cells relative to siCTL-transfected cells 72 h post-transfection, time point when cells are re-plated for clonogenic or short-term MTS assay. Results show mean values ± SD of 7 independent experiments. Right panel Cell viability measured by MTS viability assays 144 h post-transfection. Results show the percentage of viability relative to cells transfected with siCTL from 3 independent experiments. Lower panel PARG and BRCA1 depletions were verified by western blot at the times indicated. b Clonogenic survival (left panel) of U2OS cells after single or combined siRNA-mediated depletion of BRCA1 and PARG. Results are depicted as box plots showing distribution of data from 4 individual experiments. Percentage of viable cells relative to siCTL-transfected cells 72 h post-transfection (right panel). Results show mean values ± SD of 5 independent experiments. PARG and BRCA1 depletions at 72 h were verified by western blot (middle panel). BRCA1 specific signal is indicated by arrowhead. p: *** < 0.001; 0.001 < ** < 0.01; 0.01 < * < 0.05; 0.05 < ns, not significant